Fang Karen Kai-Lin, Lee Jong Bok, Zhang Li
Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Cancers (Basel). 2022 Dec 23;15(1):94. doi: 10.3390/cancers15010094.
T-cell malignancies are often aggressive and associated with poor prognoses. Adoptive cell therapy has recently shown promise as a new line of therapy for patients with hematological malignancies. However, there are currently challenges in applying adoptive cell therapy to T-cell malignancies. Various approaches have been examined in preclinical and clinical studies to overcome these obstacles. This review aims to provide an overview of the recent progress on adoptive cell therapy for T-cell malignancies. The benefits and drawbacks of different types of adoptive cell therapy are discussed. The potential advantages and current applications of innate immune cell-based adoptive cell therapy for T cell malignancies are emphasized.
T细胞恶性肿瘤通常具有侵袭性,且预后较差。过继性细胞疗法最近已显示出有望成为血液系统恶性肿瘤患者的一种新的治疗方法。然而,目前将过继性细胞疗法应用于T细胞恶性肿瘤存在挑战。在临床前和临床研究中已经研究了各种方法来克服这些障碍。本综述旨在概述T细胞恶性肿瘤过继性细胞疗法的最新进展。讨论了不同类型过继性细胞疗法的优缺点。强调了基于先天免疫细胞的过继性细胞疗法对T细胞恶性肿瘤的潜在优势和当前应用。
Cancers (Basel). 2022-12-23
J Immunol Res. 2017-1-2
Trends Pharmacol Sci. 2021-1
Front Immunol. 2021
Clin Pharmacol Ther. 2019-11-25
Korean J Clin Oncol. 2024-12
J Immunother Cancer. 2023-9
Front Immunol. 2022
Front Immunol. 2022